Study on the Efficacy and Mechanism of METTL3 Peptide Inhibitors in Enhancing Anti-tumor Immune Response by Reshaping the Tumor Microenvironment

Sponsor
Xijing Hospital
Study ID
NCT06762925
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • No Interventions — OTHER
    No Interventions

Study Details

This study aims to validate the accuracy and clinical value of METTL3 as a biomarker for predicting immune therapy response in patients with urinary tract tumors through observational studies.

Key Dates

First listed
Jan 8, 2025
Start date
Jan 30, 2025
Status verified
Dec 2024
Primary completion
Jun 1, 2026
Completion
Jun 1, 2026

Study Design

Enrollment
450 participants (estimated)

Arms

  • Arm: Bladder Cancer
  • Arm: Prostate Cancer
  • Arm: Kidney Cancer

Primary Outcome Measure

The expression levels of METTL3 and ANGPTL2 [ Time Frame: About a year and a half ]

Central Contacts

Find similar trials

Nationwide
Bladder cancer trialsKidney cancer trialsProstate cancer trialsOncology trialsUrology trialsProstate oncology trialsMen's health trials

Related Studies